Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest update is out from Bicycle Therapeutics ( (BCYC) ).
On June 17, 2025, Bicycle Therapeutics held its annual general meeting where all proposals, including director re-elections and auditor appointments, were approved by shareholders. The meeting saw high shareholder participation, with approximately 98.63% of shares represented, reflecting strong support for the company’s governance and strategic direction.
The most recent analyst rating on (BCYC) stock is a Buy with a $42.00 price target. To see the full list of analyst forecasts on Bicycle Therapeutics stock, see the BCYC Stock Forecast page.
Spark’s Take on BCYC Stock
According to Spark, TipRanks’ AI Analyst, BCYC is a Neutral.
Bicycle Therapeutics’ score is primarily driven by its strong revenue growth and promising corporate developments in its radiopharmaceutical pipeline. However, financial challenges, including net losses and reliance on external financing, weigh on the score. The technical analysis suggests neutral market conditions, while valuation metrics indicate potential overvaluation.
To see Spark’s full report on BCYC stock, click here.
More about Bicycle Therapeutics
Bicycle Therapeutics plc operates in the biotechnology industry, focusing on developing novel therapies based on its proprietary bicyclic peptide technology. The company is dedicated to creating transformative medicines for diseases with significant unmet medical needs.
Average Trading Volume: 346,399
Technical Sentiment Signal: Sell
Current Market Cap: $556.4M
For an in-depth examination of BCYC stock, go to TipRanks’ Overview page.